December 15, 2023 06:47 AM ESTUpdated 10:45 AM
R&D

Re­neo’s PhI­Ib rare dis­ease tri­al fail­ure forces lay­offs, cost cuts — stock plum­mets

Ayisha Sharma

News Reporter

Re­neo Phar­ma­ceu­ti­cals’ stock plunged by 82% as it re­vealed plans to slash 70% of its work­force af­ter its on­ly drug can­di­date dis­ap­point­ed in a reg­is­tra­tional …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times